The aim of this study is to provide long-term real-world evidence on long-acting injectable (LAI) buprenorphine-treated
patients in Finland to understand the reasons for converting to LAI treatment, how LAI is used in clinical practice,
(including treatment trajectory), and to clarify unclear measures of treatment success.
Changes to the permit: change of processors
Issuer of the original permit: Findata